• Mon. Nov 30th, 2020

Pharma Oracle

Evolving Today for better Tomorrow

Ondesk figure discussion: DexCom, Inc. (NASDAQ: DXCM)

ByCandice Hansen

Mar 13, 2020 , ,

On Thursday, DexCom, Inc. (NASDAQ: DXCM) stock observed trading -19.26% off 52-week high price. On the other end, the stock has been noted 130.49% away from low price over the last 52-weeks. The stock disclosed a move of -1.89% away from 50 day moving average and 31.80% away from 200 day moving average. Moving closer, we can see that shares have been trading -11.42% off 20-day moving average.

DexCom, Inc. (DXCM) recently stated its financial results as of and for the quarter and fiscal year ended December 31, 2019.

Fourth Quarter 2019 Highlights:

Revenue grew 37% versus the same quarter of the previous year to $462.8M

U.S. revenue growth of 34% and international revenue growth of 52%

GAAP operating income of $101.5M or 21.9% of revenue. Non-GAAP operating income* of $103.6M or 22.4% of revenue

Commenced launch of G6 into Medicare

Full Year 2019 Highlights:

Full year revenue grew 43% versus the previous year to $1,476.0M

U.S. revenue growth of 42% and international revenue growth of 48%

GAAP operating income of $142.3M or 9.6% of revenue. Non-GAAP operating income* of $161.3M or 10.9% of revenue

Doubled G6 sensor manufacturing capacity

Fourth Quarter 2019 Financial Results

Revenue: In the fourth quarter of 2019, worldwide revenue grew 37% to $462.8M, up from $338.0M in the fourth quarter of 2018. Volume growth in conjunction with strong new patient additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases.

Gross Profit: Gross profit totaled $309.3M or 66.8% of sales for the fourth quarter of 2019, contrast to $222.8M or 65.9% of sales in the fourth quarter of 2018.

Operating Income: GAAP operating income for the fourth quarter of 2019 was $101.5M, contrast to a GAAP operating loss of $164.6M for the fourth quarter of 2018.

Non-GAAP operating income* for the fourth quarter of 2019 was $103.6M, contrast to a non-GAAP operating income of $54.4M for the fourth quarter of 2018.

Net Income and Net Income per Share: GAAP net income was $92.7M, or $1.00 per diluted share, for the fourth quarter of 2019, contrast to GAAP net loss of $179.7M, or $2.03 per diluted share, for the same quarter of 2018. GAAP net loss for the fourth quarter of 2018 included the $217.7M non-cash charge related to the amended Verily contract.

Non-GAAP net income* was $106.5M, or $1.15 per diluted share, for the fourth quarter of 2019, contrast to a non-GAAP net income of $50.2M, or $0.56 per diluted share, for the same quarter of 2018. The fourth quarter 2019 non-GAAP amount excludes $11.7M of non-cash interest expense related to Dexcom’s senior convertible notes, $1.3M of business transition and related costs and $0.8M of amortization of intangible assets. The fourth quarter 2018 non-GAAP amount excludes the $217.7M non-cash charge related to the amended Verily contract, $6.0M of non-cash interest expense related to Dexcom’s senior convertible notes, $4.9M of loss from equity investments, $0.8M of business transition and related costs and $0.5M of amortization of intangible assets.

Cash and Liquidity: As of December 31, 2019, Dexcom held $1,533.3M in cash and marketable securities and our revolving credit facility remains undrawn. The cash balance represents important financial and planned flexibility as Dexcom continues to expand production capacity and explore new market opportunities.

 The USA based company DexCom, Inc. moved with change of -1.89% to $247.64 with the total traded volume of 1713566 shares in recent session versus to an average volume of 992.44K. DXCM’s shares are at 14.90% for the quarter and driving a 67.94% return over the course of the past year and is now at 13.21% since this point in 2018.

Leave a Reply

Your email address will not be published. Required fields are marked *